scholarly journals Full-term pregnancy in breast cancer survivor with fertility preservation: A case report and review of literature

2019 ◽  
Vol 7 (1) ◽  
pp. 58-68 ◽  
Author(s):  
Marta Garrido-Marín ◽  
Pedro Maria Argacha ◽  
Luís Fernández ◽  
Florencia Molfino ◽  
Fina Martínez-Soler ◽  
...  
2020 ◽  
pp. 21-22
Author(s):  
Sharma Jyoti ◽  
Damini Sharma

Introduction: Breast cancer is one of the common cancers & is responsible for leading cause of cancer death among the women worldwide. The risk of local and distant recurrence is the highest during the first two years post initial treatment. Late relapse is uncommon in breast cancer survivors. Case Report We report a case of 48-year-old breast cancer survivor reporting 12 years after being treated for left sided breast cancer. She reported with c/o shortness of breath and backache as her chief complaint. CECT Thorax revealed well defined lobulated soft tissue lesion in rt subdiaphragmatic para sternal location. Biopsy and IHC from this mass revealed adenocarcinoma consistent with breast origin with ER, PR positivity. Conclusion: The question arises that is lifelong follow up required in ca breast patients as late relapses are not quite common but can arise at any stage in breast cancer.


2019 ◽  
Vol Volume 11 ◽  
pp. 9743-9748 ◽  
Author(s):  
Huan Lin ◽  
Jiahuai Wen ◽  
Lixia Hong ◽  
Ying Chen ◽  
Yannan Wu ◽  
...  

2013 ◽  
Vol 149 (8) ◽  
pp. 973
Author(s):  
Sarah Yagerman ◽  
Melissa Pulitzer ◽  
Philip Spencer ◽  
Ashfaq Marghoob

Breast Care ◽  
2016 ◽  
Vol 11 (6) ◽  
pp. 424-426 ◽  
Author(s):  
Arpine Gevorgyan ◽  
Giacomo Bregni ◽  
Giulia Galli ◽  
Elisa Zanardi ◽  
Filippo de Braud ◽  
...  

Background: Neuroendocrine carcinoma is an uncommon histology for breast cancer. Case Report: Our patient underwent right quadrantectomy for a neuroendocrine carcinoma in 1984 and had a bone relapse 30 years later. After thorough pathological and immunohistochemical analysis the diagnosis was confirmed and HER2 amplification was observed. Here we discuss the management, rationale and results of HER2-targeted therapy in advanced neuroendocrine breast carcinoma.


Sign in / Sign up

Export Citation Format

Share Document